The Latest Cardiac and Vascular News
FRANKLIN LAKES, N.J., Nov. 7, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the safety and efficacy data from the LUTONIX® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-knee (BTK) indication. The clinical study is a prospective, global, multicenter, randomized, controlled trial comparing the […]
SALT LAKE CITY–(BUSINESS WIRE)–XableCath, a commercial-stage medical device company, announced today that it has demonstrated initial safety and efficacy of its unique catheters for use with chronic venous occlusions, commonly characterized by recalcitrant lesions that have historically proven difficult to cross with standard catheter technologies. XableCath catheters are FDA-cleared for […]
VANCOUVER, Nov. 7, 2018 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and […]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company’s SurVeil® drug-coated balloon (DCB) was shared in a late-breaking clinical trial presentation at the Vascular Interventional Advances (VIVA) 2018 […]
• New study to determine if the FLEX Dynamic Scoring Catheter™ reduces dissections and the need for bailout stents in peripheral arteries • 15 patients to be evaluated by Dr. Nicolas W. Shammas at the UnityPoint Trinity in Bettendorf, Iowa • More than 12 million people in the US and […]
WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced at the 15th annual VIVA conference in Las Vegas that its Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial successfully achieved both primary and secondary endpoints. One year results from the TOBA II study were presented […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia® [OTC: BCDA] today announced that Mark Schwartz, a 25-year veteran of cardiovascular device development, has joined the company as Vice President of Clinical Affairs, effective November 1. Schwartz brings extensive leadership experience in the design and execution of clinical studies for medical devices in the heart […]
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update and reported financial results for the third quarter ended September 30, 2018. “REVA has achieved two technological milestones […]
TEL AVIV, Israel, Nov. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the third quarter ending September 30, 2018. Third Quarter 2018 highlights: […]
LONDON, Nov. 6, 2018 /PRNewswire/ — Based on its recent analysis of the global cardiac protein biomarker research market, Frost & Sullivan recognises Olink Proteomics with the 2018 Global Enabling Technology Leadership Award for developing its cardiovascular (CV) multiplex panels—CVD II and CVD III—featuring its proprietary Proximity Extension Assay (PEA) technology. The CVD II […]
